Denali Therapeutics Inc.
DNLI
$20.54
-$0.16-0.77%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -3.97% | -0.73% | |||
| Gross Profit | 3.97% | 0.73% | |||
| SG&A Expenses | 11.21% | 9.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.05% | 1.83% | |||
| Operating Income | 0.05% | -1.83% | |||
| Income Before Tax | -1.22% | -2.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.30% | -2.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.30% | -2.24% | |||
| EBIT | 0.05% | -1.83% | |||
| EBITDA | -0.01% | -1.96% | |||
| EPS Basic | 0.46% | -1.67% | |||
| Normalized Basic EPS | -0.74% | -1.66% | |||
| EPS Diluted | 0.46% | -1.67% | |||
| Normalized Diluted EPS | -0.74% | -1.66% | |||
| Average Basic Shares Outstanding | 1.76% | 0.57% | |||
| Average Diluted Shares Outstanding | 1.76% | 0.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||